emergency use authorization approved

Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test

April 20, 2021

Greensboro, N.C.-based Qorvo Biotechnologies has received FDA Emergency Use Authorization (EUA) for its rapid Omnia SARS-CoV-2 Antigen Test.

The test platform, which includes a portable test instrument and microfluidic cartridge, is authorized for using nasal swabs to qualitatively detect the presence of SARS-CoV-2 viral antigens.

The rapid test uses high-frequency acoustic wave sensors to deliver results in approximately 20 minutes.

View today's stories